If I Could Use Gene Therapy to Cure My Manic-Depression, I Don’t Know Whether I Would
By Tana Wojczuk,
Slate
| 09. 21. 2021
In the final chapter of her 1995 memoir of manic-depression, An Unquiet Mind, Kay Redfield Jamison posed a question that has stayed on my mind ever since: “I have often asked myself whether, given the choice, I would choose to have manic-depressive illness.” The question haunts me because I can’t answer it, either.
When Jamison first posed her question (if there were a cure for my mental illness, would I take it?), it seemed like pure speculation. But the question is no longer so hypothetical.
In June, the journal Nature Reviews Neurology published the results of a wide-ranging study of the genetic roots of manic depression. The study included 40,000 cases and identified a startling 64 genes associated with the disease. (In a clinical setting, the disease is usually referred to as “bipolar disorder,” though I’ve always preferred the more descriptive “manic-depression.”) Studies like this one are part of a burgeoning discipline known as molecular psychiatry, a field that studies the “biological mechanisms underlying psychiatric disorders.” Molecular biologists are also making progress in studies of major (unipolar)...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...